Recap: Amneal Pharmaceuticals Q1 Earnings - Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals AMRX reported its Q1 earnings results on Friday, May 5, 2023 at 06:00 AM.

Here's what investors need to know about the announcement.

Amneal Pharmaceuticals beat estimated earnings by 20.0%, reporting an EPS of $0.12 versus an estimate of $0.1.

Revenue was up $59.91 million from the same period last year.

Last quarter the company beat on EPS by $0.02 which was followed by a 3.52% drop in the share price the next day.

Here's a look at Amneal Pharmaceuticals's past performance:

Quarter	Q4 2022	Q3 2022	Q2 2022	Q1 2022
EPS Estimate	0.21	0.18	0.20	0.13
EPS Actual	0.23	0.14	0.19	0.12
Revenue Estimate	579.91M	564.15M	536.34M	503.97M
Revenue Actual	609.76M	545.56M	559.36M	497.63M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Amneal Pharmaceuticals management provided guidance for FY 2023, expecting earnings between $0.4 and $0.5 per share.

To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.